论文部分内容阅读
目的 探讨蛋白激酶C(PKC)、PKCα在肾盂输尿管癌中表达的临床意义。 方法 采用免疫组化SABC法和原位杂交技术检测 45例肾盂输尿管癌中PKC、PKCα表达。 结果 肾盂输尿管癌PKC、PKCα阳性表达率分别为 6 0 .0 %和 5 7.8%。其中T2 ～T3 为 6 8.6 % (2 4/ 35 )、6 8 6 %(2 4/ 35 ) ,T1为 30 .0 % (3/ 10 )、2 0 0 % (2 / 10 ) ,P <0 .0 5。G2 ～G3 患者为 6 6 .7% (2 6 / 39)、6 1 4% (2 5 /39) ,G1为 16 .7% (1/ 6 )、16 7(1/ 6 ) ,P <0 .0 5。术后再发膀胱癌者PKC、PKCα阳性表达率为 83 3 %(15 / 18)、77 8% (14/ 18) ,术后未再发者PKC、PKCα阳性表达率为 44 4% (12 / 2 7)、44 .4% (12 / 2 7) ,P<0 0 5。PKC、PKCα阳性表达者生存率明显低于阴性表达者 ,P <0 0 5。 结论 PKC、PKCα阳性表达与肾盂输尿管癌病理分期、细胞分级、术后再发膀胱癌及预后有关 ,可能是其判断预后的指标之一
Objective To investigate the clinical significance of protein kinase C (PKC) and PKCα expression in renal pelvis and ureter cancer. Methods Immunohistochemical SABC method and in situ hybridization were used to detect the expression of PKC and PKCα in 45 cases of ureteropelvic cancer. Results The positive rates of PKC and PKCα in ureteropelvic cancer were 60.0% and 57.8% respectively. The T2 ~ T3 was 66.6% (2 4/35), 6 8 6% (2 4/35), T1 was 30.0% (3/10), 200% (2/10), P < 0 .0 5. The patients with G2-G3 had a positive rate of 66.7% (26/39), 61.4% (25/39), G1 16.7% (1/6), and 16 7 (1/6), P < 0 .0 5. The positive rates of PKC and PKCα in patients with recurrent bladder cancer were 83.3% (15/18) and 77.8% (14/18) respectively. The positive rates of PKC and PKCα were 44.4% (12 / 2 7), 44.4% (12/2 7), P <0 0 5. The survival rates of PKC and PKCα positive patients were significantly lower than those of negative ones (P <0.05). Conclusions The positive expression of PKC and PKCα may be related to the pathological stage, cell grade, recurrent bladder cancer and prognosis of ureteropelvic carcinoma, which may be one of the indicators of prognosis